Alvotech (ALVO) Files First Known EMA Bid for Eylea 8mg Biosimilar
Alvotech submitted AVT29, a proposed biosimilar to Eylea 8 mg, to the EMA as a line extension to Mynzepli. The company says this is the first known regulatory submission globally for an Eylea 8 mg biosimilar.Material DetailsContext by AI AnalystThis is an early regulatory step expanding Alvotech’s…